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Abstract
Omega-3 fatty acids play a critical role in the development and function of the central nervous
system. Emerging research is establishing an association between omega-3 fatty acids (alpha-
linolenic, eicosapentaenoic, docosahexaenoic) and major depressive disorder. Evidence from
epidemiological, laboratory and clinical studies suggest that dietary lipids and other associated
nutritional factors may influence vulnerability and outcome in depressive disorders. Research in this
area is growing at a rapid pace. The goal of this report is to integrate various branches of research
in order to update mental health professionals.
Introduction
Major depressive disorder (MDD) is a recurrent, debilitat-
ing, and potentially life threatening illness. Over the last
100 years, the age of onset of major depression has
decreased, and its overall incidence has increased in West-
ern countries. The increases in depression, up to 20-fold
higher post 1945, cannot be fully explained by changes in
attitudes of health professionals or society, diagnostic cri-
teria, reporting bias, institutional or other artifacts [1,2]
Despite advances in pharmacotherapy, and the increasing
sophistication of cognitive/behavioral interventions,
there are many patients with MDD who remain treatment
resistant [3].
Depression is undoubtedly an extremely complex and
heterogeneous condition. This is reflected by the non-uni-
versal results obtained using cognitive-behavior and anti-
depressant medications. As research continues to mount,
it is becoming clear that neurobiology/physiology, genet-
ics, life stressors, and environmental factors can all con-
tribute to vulnerability to depression. While much
attention has been given to genetics and life stressors, only
a small group of international researchers have focused on
nutritional influences on depressive symptoms. Collec-
tively, the results of this relatively small body of research
indicate that nutritional influences on MDD are currently
underestimated [4]. Omega-3 fatty acids in particular rep-
resent an exciting area of research, with eicosapentaenoic
acid (EPA) emerging as a new potential agent in the treat-
ment of depression [5].
Omega-3 fatty acids
Omega-3 fatty acids are long-chain, polyunsaturated fatty
acids (PUFA) of plant and marine origin. Because these
essential fatty acids cannot be synthesized by the human
body, they must be derived from dietary sources. Flaxseed,
hemp, canola and walnut oils are all generally rich sources
of the parent omega-3, alpha linolenic acid (ALA). Dietary
ALA can be metabolized in the liver to the longer-chain
omega-3 eicosapentaenoic (EPA) and docosahexaenoic
acid (DHA). This conversion is limited in human beings,
it is estimated that only 5–15% of ALA is ultimately
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converted to DHA [6]. Aging, illness and stress, as well as
excessive amounts of omega-6 rich oils (corn, safflower,
sunflower, cottonseed) can all compromise conversion
[7]. Dietary fish and seafood provide varying amounts of
pre-formed EPA and DHA as highlighted in Table 1.
The dietary intake of omega-3 fatty acids has dramatically
declined in Western countries over the last century, the
North American diet currently has omega-6 fats outnum-
bering omega-3 by a ratio of up to 20:1. There are a
number of reasons for this skewed ratio, most notably the
mass introduction of the aforementioned omega-6 rich
oils into the food supply, either directly or through ani-
mal rearing practices [8]. The ideal dietary ratio of omega-
6 to omega-3 has been recommended by an international
panel of lipid experts to be approximately 2:1 [9]. Given
that approximately 20% of the dry weight of the brain is
made up of PUFA and that one out of every three fatty
acids in the central nervous system (CNS) are PUFA, the
importance of these fats cannot be argued [7]. Consider-
ing that highly-consumed vegetable oils have significant
omega-6 to omega-3 ratios (see Table 2), it is quite plau-
sible that, for some individuals, inadequate intake of
omega-3 fatty acids may have neuropsychiatric conse-
quences. While far from robust at this time, emerging
research suggests that omega-3 fatty acids may be of ther-
apeutic value in the treatment of depression.
Epidemiological Data
A number of epidemiological studies support a connec-
tion between dietary fish/seafood consumption and a
lower prevalence of depression. Significant negative corre-
lations have been reported between worldwide fish con-
sumption and rates of depression [10]. Examination of
fish/seafood consumption throughout nations has also
been correlated with protection against post-partum
depression [11], bipolar disorder [12] and seasonal affec-
tive disorder [13]. Separate research involving a random
Table 1: Various Sources of EPA and DHA
Fish/Seafood Total EPA/DHA (mg/100 g)
Mackerel 2300
Chinook salmon 1900
Herring 1700
Anchovy 1400
Sardine 1400
Coho salmon 1200
Trout 600
Spiny lobster 500
Halibut 400
Shrimp 300
Catfish 300
Sole 200
Cod 200
USDA Nutrient Database http://www.nal.usda.gov/fnic/foodcomp/search/
Table 2: Omega-6 and Omega-3 Content (%) of Dietary Oils
Oil Omega-6 Omega-3
Safflower 75 0
Sunflower 65 0
Corn 54 0
Cottonseed 50 0
Sesame 42 0
Peanut 32 0
Soybean 51 7
Canola 20 9
Walnut 52 10
Flax 14 57
USDA Nutrient Database http://www.nal.usda.gov/fnic/foodcomp/search/Lipids in Health and Disease 2004, 3:25 http://www.lipidworld.com/content/3/1/25
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sample within a nation confirms the global findings, as
frequent fish consumption in the general population is
associated with a decreased risk of depression and suicidal
ideation [14]. In addition, a cross-sectional study from
New Zealand found that fish consumption is significantly
associated with higher self-reported mental health status
[15].
Not all studies support a connection between omega-3
intake and mood. A recent cross-sectional study of male
smokers, using data collected between 1985 and 1988,
indicated that subjects reporting anxiety or depressed
mood had higher intakes of both omega-3 and omega-6
fatty acids [16]. In a large population-based study of older
males aged 50–69, there was no association between die-
tary intake of omega-3 fatty acids or fish consumption and
depressed mood, major depressive episodes, or suicide
[17].
The epidemiological studies which support a connection
between dietary fish and depression clearly do not prove
causation. There are a number of cultural, economic and
social factors which may confound the results. Most sig-
nificantly, those who do consume more fish may gener-
ally have healthier lifestyle habits, including exercise and
stress management. Despite the limitations, the epidemi-
ological data certainly justify a closer examination of
omega-3 fatty acids in those actually with depression.
Omega-3 status in MDD
There are a number of methods used to determine EFA sta-
tus in the human body, notably the plasma and red blood
cell (RBC) phospholipids. These are a reflection of dietary
fatty acid intake within the preceding few weeks. While
not identical, significant correlations exist between blood
and brain phospholipids. A number of studies have found
decreased omega-3 content in the blood of depressed
patients [18-21]. Furthermore, the EPA content in RBC
phospholipids is negatively correlated with the severity of
depression, and the omega-6 arachidonic acid to EPA
ratio positively correlates with the clinical symptoms of
depression [18].
More recently, investigators have been utilizing adipose
tissue as a longer term measurement of EFA intake (1–3
years). In a study of 150 elderly males from Crete, the par-
ent omega-3 ALA adipose tissue stores were negatively
correlated with depression [22]. A separate study found a
negative correlation between adipose tissue DHA and
rates of depression. In this case, mildly depressed adults
had 34.6 percent less DHA in adipose tissue than non-
depressed subjects [23].
Relationships between omega-3 status and post-partum
depression have also been investigated. In a cohort of 380
Australian women, plasma DHA was investigated at 6
months post-partum. Logistic regression analysis indi-
cated that a 1% increase in plasma DHA was associated
with a 59% reduction in the reporting of depressive symp-
toms [24]. It is well known that during pregnancy there is
a significant transfer (up to 2.2 g/day) EFAs to the devel-
oping fetus [7]. Increased risk of post-partum depressive
symptoms has recently been associated with a slower nor-
malization of DHA levels after pregnancy [25].
Suicide attempts have also been associated with low levels
of RBC EPA. In a study involving 100 suicide attempt
cases in China compared to 100 hospital admission con-
trols, there was an eightfold difference in suicide attempt
risk between the lowest and highest RBC EPA level quar-
tiles [26]. The seasonality of depression and suicide has
been described by investigators, with more deaths in
spring and summer vs.autumn and winter. Total serum
cholesterol has been highly significantly synchronized
with the annual rhythms in violent suicide deaths [27].
Recently, investigators found that EFA levels also vary by
season, with peaks of EPA and DHA from August to Sep-
tember. The parent omega-3 and 6 levels did not have a
seasonal variation, suggesting a seasonal interference with
delta-5-desaturase conversion. The authors of this study
suggest that the seasonal variation in EPA or DHA may, in
part, explain seasonality of violent suicide occurrence
[28].
The overlap between cardiovascular disease and depres-
sion has also been noted, with omega-3 status emerging as
a common thread. Indeed, major depression in acute cor-
onary syndrome patients is associated with significantly
lower plasma levels of omega-3 fatty acids, particularly
DHA [29]. In addition, elevated homocysteine levels, a
known risk factor for cardiovascular disease, has been
associated with the excess omega-6 fatty acids found in
the Western diet [30]. Finally, lowered intake of the parent
omega-3 ALA has been associated with depression in 771
Japanese patients with newly diagnosed lung cancer [31].
It is important to note that not every study supports an
association between lowered omega-3 status and depres-
sion. Two studies have actually shown significant
increases in plasma and RBC omega-3 status among
depressed patients [32,33]. A recent study involving
depressed adolescent patients found no significant rela-
tionship between adipose tissue EFA levels and depres-
sion [34].
Possible mechanisms of omega-3 EFA
Detailed reviews of the possible neurobehavioral mecha-
nisms of omega-3 fatty acids have been previously pub-
lished and are beyond the scope of this review [35,36].
The influence of omega-3 fatty acids within the CNS is farLipids in Health and Disease 2004, 3:25 http://www.lipidworld.com/content/3/1/25
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from completely understood, and our current knowledge
is largely based on the consequences of omega-3 defi-
ciency within animal models. There are two major areas of
omega-3 fatty acid influence worthy of further discussion.
The first is the importance of omega-3 fatty acids in neu-
ronal membranes. Omega-3 fatty acids are an essential
component of CNS membrane phospholipid acyl chains
and are therefore critical to the dynamic structure and
function of neuronal membranes [37]. Proteins are
embedded in the lipid bi-layer of the cell and the confor-
mation or quaternary structure of these proteins is sensi-
tive to the lipid components. The proteins in the bi-layer
have critical cellular functions as they act as transporters
and receptors. Omega-3 fatty acids can alter membrane
fluidity by displacing cholesterol from the membrane
[38]. An optimal fluidity, influenced by EFAs, is required
for neurotransmitter binding and the signaling within the
cell [39]. EFAs can act as sources for second messengers
within and between neurons [35].
The second area where omega-3 fatty acids may exert sig-
nificant influence in major depression is via cytokine
modulation. A growing body of research has documented
an association between depression and the production
these proinflammatory immune chemicals. These
cytokines, including interleukin-1 beta (IL-1β), -2 and -6,
interferon-gamma, and tumor necrosis factor alpha
(TNFα), can have direct and indirect effects on the CNS.
Some of the documented activities of these cytokines
include lowered neurotransmitter precursor availability,
activation of the hypothalamic-pituitary axis, and altera-
tions of the metabolism of neurotransmitters and neuro-
transmitter mRNA [40]. Researchers have found
elevations of IL-1β, and TNFα are associated with the
severity of depression [41]. Psychological stress can cause
an elevation of these cytokines. It is worth noting that var-
ious tricyclic and selective serotonin re-uptake inhibiting
antidepressants can inhibit the release of these inflamma-
tory cytokines [40].
Omega-3 fatty acids, and EPA in particular, are well docu-
mented inhibitors of proinflammatory cytokines such as
IL-1 β and TNFα. In addition, it has recently been sug-
gested that the anti-inflammatory role of omega-3 fatty
acids may influence brain derived neurotrophic factor
(BDNF) in depression [36]. BDNF is a polypeptide that
supports the survival and growth of neurons through
development and adulthood. Serum BDNF has been
found to be negatively correlated with the severity of
depressive symptoms [42]. Antidepressant medications
and voluntary exercise can enhance BDNF, while diets
high in saturated fat and sucrose, and psychological stress
inhibit BDNF production [36].
Clinical evidence
The epidemiological and laboratory studies, along with
the research which shows depressed patients appear to
have lowered omega-3 status, have naturally led to clinical
investigations. A number of case reports have appeared in
the literature, the first of which was over 20 years ago. In
this initial series of case reports, flaxseed oil (source of the
parent omega-3 ALA) at various dosages, was reported to
improve the symptoms of bipolar depression and agora-
phobia [43]. An additional case report documented an
improvement in depressive symptoms during pregnancy
with the use of 4 g EPA/2 g DHA per day. Interestingly,
improvements in symptoms (measured via the Hamilton
Rating Scale for depression – HRDS) occurred at four
weeks, and with the exception of insomnia and anxious
thoughts, all symptoms resolved at six weeks [44].
Despite the interesting results, there are major scientific
problems with case reports, most notably the placebo
response. A recently published case report published took
advantage of modern brain imaging to corroborate clini-
cal improvements. In this case a patient with treatment
resistant depression was placed on a daily dose of 4 g pure
EPA, and after one month there were significant improve-
ments, including a co-morbid social phobia. After nine
months the patient was reportedly symptom free. It was
found that over the course of the nine months of treat-
ment, there was a 53 percent increase in cerebral phos-
phomonoesters and the ratio of cerebral
phosphomonoesters to phosphodiesters increased 79 per-
cent, indicating reduced neuronal phospholipid turnover.
Utilizing MRI technology, the researchers found that the
EPA treatment was associated with structural brain
changes, including a reduction in lateral ventricular vol-
ume. This is likely to be a result of increased phospholipid
biosynthesis and reduced phospholipid breakdown [45].
Given the recent research indicating a decrease in volume
in various areas of the brain of depressed patients, this is
certainly an important case study [46].
A series of case reports also suggest that 1 – 4 g of pure EPA
may be helpful in anorexia nervosa, a condition with the
highest risk of morbidity and mortality among psychiatric
disorders [47]. In all six of the cases, EPA was reported to
improve mood to varying degrees. For some, discontinu-
ing EPA therapy resulted in deteriorations in mood and
other psychiatric symptoms.
An interesting study examined fish oil vs.marine oil
extracted from Antarctic krill in premenstrual syndrome.
Krill is similar to fish oil, with the exception that it
contains naturally-occurring phospholipids, and contains
more EPA per gram than standard fish oil capsules (240
mg/g EPA in krill vs.180 mg/g in standard fish oil). In the
3-month trial, patients (n = 70) received 2 g of krill oil orLipids in Health and Disease 2004, 3:25 http://www.lipidworld.com/content/3/1/25
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2 g fish oil daily for one month, then for eight days prior
to, and two days during, menstruation for the following
two months. Evaluation at 45 days and three months
showed that krill oil significantly improved depressive
symptoms of premenstrual syndrome. The absence of sig-
nificant effects of fish oil on mood suggests that the pres-
ence of the phospholipids and/or higher amounts of EPA
may be responsible for the therapeutic effect of krill oil
[48].
There have been some controlled studies that have exam-
ined omega-3 fatty acids and a placebo intervention in
depression. The first small clinical study (n = 30) showed
that four months of treatment with 9.6 g of omega-3 fatty
acids (6.2 g EPA/3.4 g DHA) was of therapeutic value in
bipolar disorder. Specifically, this study showed a highly
significant effect in treating depression (p < 0.001 HRSD
scores) [49]. In a separate double-blind, placebo-control-
led study (n = 22), the addition of 2 g of pure EPA to
standard antidepressant medication enhanced the effec-
tiveness of that medication vs.medication and placebo.
This 3-week study, involving patients with treatment-
resistant depression, showed that EPA had an effect on
insomnia, depressed mood, and feelings of guilt and
worthlessness. There were no clinically relevant side
effects noticed [50].
In a small pilot study (n = 30), Harvard researchers found
that just 1 g of EPA could reduce aggression (modified
Overt Aggression Scale) and depressive symptom scores
(Montgomery-Asberg Depression Rating Scale) among
borderline personality disorder patients. The results of
this 2-month, placebo-controlled study are encouraging,
given the difficulty in treating borderline personality dis-
order. It is also of note that 90 percent of participants
remained in the study and no clinically relevant side
effects were noticed with EPA [51].
In a double-blind, placebo-controlled trial over two
months, high dose fish oil (9.6 g/day) was added to stand-
ard antidepressant therapy in 28 patients with MDD. In
this study the patients who received the omega-3 fish oil
capsules had a significantly decreased score on the HRSD
compared to those taking the placebo. Once again, the
fish oil, even at this high dose, was well tolerated with no
adverse events reported [52].
Various doses of pure EPA have also been investigated in
depression. In a 12-week, randomized, double-blind, pla-
cebo-controlled study, patients (n = 70) were given ethyl-
EPA at doses of 1 g, 2 g or 4 g. The patients in this case had
experienced persistent depression, despite ongoing stand-
ard antidepressant pharmacotherapy at adequate does.
Interestingly, in this study, "less was more." Those in the
1 g per day group had the best outcome. The patients who
received 1 g per day of EPA were the only group to show
statistically significant improvements. Among the 1 g/day
group, 53 percent achieved a 50 percent reduction in
HRSD scores. The 1 g EPA led to improvements in depres-
sion, anxiety, sleep, lassitude, libido, and suicidal idea-
tion. These findings suggest that omega-3 fatty acids can
augment antidepressant pharmacotherapy and/or allevi-
ate depression by entirely different means than standard
medications [53]. A large study examining the effects of
omega-3 or placebo added to cognitive-behavior therapy
would be of interest.
To date, the published data on supplementation with
pure EPA on MDD or depressive symptoms have been
positive. With regard to DHA or a combination of EPA
and DHA, there have been three negative reports. A trial
on DHA alone as monotherapy in the treatment of MDD
was recently reported. In this study, 2 g pure DHA or pla-
cebo was administered to 36 patients with depression for
six weeks. The response differences between the groups, as
measured by scores on the Montgomery-Asberg Depres-
sion Rating Scale did not reach statistical significance [54].
In an open label pilot study, the combination of 1.7 g of
EPA and 1.2 g of DHA failed to show benefits among
seven women with a past history of post-partum depres-
sion. The omega-3 monotherapy was initiated between
the 34th  – 36th  week of pregnancy and was assessed
through 12 weeks post-partum. In these women the fish
oil combination did not reduce the risk of relapse [55].
Finally, a pure DHA supplement, at low doses of 200 mg
per day for 4 months post-partum, did not improve self-
rated or diagnostic measures of depression over placebo.
However, the women enrolled (n = 89) in this study were
not clinically depressed as a group, which precludes inter-
pretation that DHA is ineffective in post-partum depres-
sion [56].
Other dietary considerations
It is important to consider the nutrients which can ulti-
mately influence omega-3 status. Among them, four
important dietary factors also relate to MDD: zinc, sele-
nium, folic acid and dietary antioxidants. A number of
studies have shown that zinc levels are lower among
patients with depression and a recent study found that 25
mg zinc supplementation may improve depressive symp-
toms [57]. Interestingly, 25 mg of zinc supplemented for
two months has also been shown to significantly increase
omega-3 status in the plasma phospholipids at the
expense of saturated fat [58]. Lowered levels of selenium
have been associated with negative mood scores in at least
5 studies [59]. Selenium plays a significant role in the
human antioxidant defense system. In addition, selenium
deficiency can interfere with the normal conversion of
ALA into EPA and DHA, and results in an increase in the
omega-6:omega-3 ratio [60].Lipids in Health and Disease 2004, 3:25 http://www.lipidworld.com/content/3/1/25
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Regarding folic acid, a growing body of research has doc-
umented the low levels of folic acid among patients with
depression [61]. In addition, there are small clinical trials
showing a beneficial effect of folic acid in depression, and
its ability to enhance the effectiveness of antidepressant
medications at just 500 mcg [61,62]. It is of relevance here
because folic acid has been shown to increase omega-3
status when supplemented, and decrease omega-3 status
when it is in deficiency in the animal model [63]. In addi-
tion, a folic acid deficient diet can enhance lipid peroxida-
tion [64].
In patients with MDD there are in fact signs of oxidative
stress and lipid peroxidation, and antidepressant medica-
tions may reverse the severity of oxidative stress in
depressed patients [65]. A recent human study found that
depressive symptoms are independently correlated with
lipid peroxidation [66]. Patients with obsessive compul-
sive disorder (OCD) and co-morbid depression have
higher levels of lipid peroxidation than those with OCD
alone [67]. Dietary antioxidants are known to influence
the antioxidant defense system, and new research suggests
that dietary antioxidants can influence omega-3 status.
Specifically, a diet devoid of antioxidants lowered essen-
tial fatty acid levels in the plasma of trained athletes, even
though the amount and types of fats were not altered [68].
Omega-3 fatty acids have been shown to decrease lipid
peroxidation in vivo [69], and antioxidant supplementa-
tion can prevent the negative influence of saturated fat on
BDNF levels and cognitive function in animals [70].
Conclusion
While far from robust, there is enough epidemiological,
laboratory and clinical evidence to suggest that omega-3
fatty acids may play a role in certain cases of depression.
Fish oil supplements are well tolerated, and have been
shown to be without significant side effects over large
scale, 3-year research [71]. Generally, omega-3 supple-
ments are inexpensive, which makes them an attractive
option as an adjuvant to standard care. At this time, how-
ever, the routine use of omega-3 fatty acids for the treat-
ment of MDD cannot be recommended.
The research reviewed here shows that the data is far from
unequivocal. Large trials are warranted to truly determine
efficacy, appropriate dosing and the potentially active
components – EPA, DHA, or both. It is also clear that
omega-3 intake occurs in dietary context, one that
includes other important nutrients. Future research
should consider the influence of zinc, selenium, folic acid
and dietary antioxidant status to determine who may be a
successful candidate for omega-3 supplementation.
In the meantime, given the current excess intake of
omega-6 rich oils, and the emerging research on omega-3
fatty acids and MDD, all mental health professionals
should at least ensure adequate intake of omega-3 fatty
acids among patients with MDD. The current average
North American intake of EPA and DHA is approximately
130 mg per day, well short of the minimum 650 mg rec-
ommended by the international panel of lipid experts [6].
While it is not necessary for mental health professionals to
become clinical nutritionists, consideration of a patient's
dietary quality may be worthwhile. Hopefully future
research will determine if dietary modifications or supple-
mentation can influence the outcome of standard care.
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